Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure S8 from Inhibition of PSF Activity Overcomes Resistance to Treatment in Cancers Harboring Mutant p53
  1. Home
  2. Publications
  3. Supplementary Figure S8 from Inhibition of PSF Activity Overcomes Resistance to Treatment in Cancers Harboring Mutant p53

Supplementary Figure S8 from Inhibition of PSF Activity Overcomes Resistance to Treatment in Cancers Harboring Mutant p53

Authors:
  • KTKen-Ichi Takayama
    Ken-Ichi Takayama
  • TSTomohiro Sato
    Tomohiro Sato
  • THTeruki Honma
    Teruki Honma
  • MYMinoru Yoshida
    Minoru Yoshida
  • Satoshi Inoue
    Satoshi Inoue

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1535-7163.32709997
Abstract
Supplementary Figure S8. No apparent toxic effect was observed in tissues of mice treated with C-30 for DU145 xenograft model.
Keywords
  • ENDOCRINOLOGY
  • STEROID HORMONES AND RECEPTORS
  • EPIGENETICS
  • EPIGENOMICS
  • GENE REGULATION
  • MECHANISMS OF TRANSCRIPTION
  • ONCOGENES & TUMOR SUPPRESSORS
  • P53
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.